Body fluid markers for multiple sclerosis and differential diagnosis from atypical demyelinating disorders

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–1231. doi: 10.1016/S0140-6736(02)08220-X
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31(3):233–243. doi: 10.1097/WCO.0000000000000561
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi: 10.1016/S1474-4422(17)30470-2
   PubMed Web of Science ®Google Scholar
• Kaisey M, Solomon AJ, Luu M, et al. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Multi Sclerosis Relat Disord. 2019;30:51–56. doi: 10.1016/j.msard.2019.01.048
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Akgün K, Brück W. Molecular biomarkers in multiple sclerosis. J Neuroinflammation. 2019;16(1):272. doi: 10.1186/s12974-019-1674-2
   PubMed Web of Science ®Google Scholar
• Efendi H. Clinically isolated syndromes: clinical characteristics, differential diagnosis, and management. Arch Neuropsychiatr. 2015;52(Suppl 1):S1–S11. doi: 10.5152/npa.2015.12608
   Google Scholar
• Kolčava J, Kočica J, Hulová M, et al. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study. Multi Sclerosis Relat Disord. 2020;44:102262. doi: 10.1016/j.msard.2020.102262
   PubMed Web of Science ®Google Scholar
• Bankoti J, Apeltsin L, Hauser SL, et al. In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol. 2014;75(2):266–276. doi: 10.1002/ana.24088
   PubMed Web of Science ®Google Scholar
• Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol. 2013;262(1–2):1–10. doi: 10.1016/j.jneuroim.2013.06.014
   PubMed Web of Science ®Google Scholar
• Reiber H. Flow rate of cerebrospinal fluid (CSF) — a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994;122(2):189–203. doi: 10.1016/0022-510X(94)90298-4
   PubMed Web of Science ®Google Scholar
• Auer M, Hegen H, Zeileis A, et al. Quantitation of intrathecal immunoglobulin synthesis - a new empirical formula. Eur J Neurol. 2016;23(4):713–721. doi: 10.1111/ene.12924
   PubMed Web of Science ®Google Scholar
• Simonsen CS, Flemmen HØ, Lauritzen T, et al. The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;6(1):2055217319901291. doi: 10.1177/2055217319901291
   Google Scholar
• Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21(8):1013–1024. doi: 10.1177/1352458514568827
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138(Pt 7):1863–1874. doi: 10.1093/brain/awv105
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao N, Guan H, et al. Anti-N-methyl-D-aspartate receptor encephalitis: characteristics and rapid diagnostic approach in the emergency department. BMC neurol. 2022;22(1):224. doi: 10.1186/s12883-022-02752-9
   PubMed Web of Science ®Google Scholar
• Lana-Peixoto MA, Talim N. Neuromyelitis Optica Spectrum Disorder and anti-MOG syndromes. Biomedicines. 2019;7(2):42. doi: 10.3390/biomedicines7020042
   PubMed Web of Science ®Google Scholar
• Bernitsas E, Khan O, Razmjou S, et al. Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis. PLoS One. 2017;12(7):e0181431. doi: 10.1371/journal.pone.0181431
   PubMed Web of Science ®Google Scholar
• Chu AB, Sever JL, Madden DL, et al. Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases. Ann Neurol. 1983;13(4):434–439. doi: 10.1002/ana.410130410
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. doi: 10.1186/s12974-016-0718-0
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1–2):82–90. doi: 10.1016/j.jns.2011.03.038
   PubMed Web of Science ®Google Scholar
• Bernhardt AM, Tiedt S, Teupser D, et al. A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases. EBioMedicine. 2023;89:104456. doi: 10.1016/j.ebiom.2023.104456
   PubMed Web of Science ®Google Scholar
• Fonderico M, Portaccio E, Razzolini L, et al. Cerebrospinal fluid IgM and oligoclonal IgG bands in multiple sclerosis: a meta-analysis of prevalence and prognosis. Brain Sci. 2021;11(11):1444. doi: 10.3390/brainsci11111444
   PubMed Web of Science ®Google Scholar
• Brennan KM, Galban-Horcajo F, Rinaldi S, et al. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J Neuroimmunol. 2011;238(1–2):87–95. doi: 10.1016/j.jneuroim.2011.08.002
   PubMed Web of Science ®Google Scholar
• Monreal E, La Sainz de Maza S, Costa-Frossard L, et al. Predicting aggressive multiple sclerosis with intrathecal IgM synthesis among patients with a clinically isolated syndrome. Neurol(r) Neuroimmunol Neuroinflammation. 2021;8(5):e1047. doi: 10.1212/NXI.0000000000001047
   PubMed Web of Science ®Google Scholar
• Villar LM, Masjuan J, González-Porqué P, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59(4):555–559. doi: 10.1212/WNL.59.4.555
   PubMed Web of Science ®Google Scholar
• Ferraro D, Simone AM, Bedin R, et al. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol. 2013;257(1–2):76–81. doi: 10.1016/j.jneuroim.2013.01.011
   PubMed Web of Science ®Google Scholar
• Reiber H. Cerebrospinal fluid-physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4(3):99–107. doi: 10.1177/135245859800400302
   PubMedGoogle Scholar
• Sádaba MC, Rothhammer V, Muñoz Ú, et al. Serum antibodies to phosphatidylcholine in MS. Neurol(r) Neuroimmunol Neuroinflam-mation. 2020;7(4):e765. doi: 10.1212/NXI.0000000000000765
   PubMed Web of Science ®Google Scholar
• Sánchez-Vera I, Escudero E, Muñoz Ú, et al. IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment. Ther Adv Neurol Disord. 2023;16:17562864231189919. doi: 10.1177/17562864231189919
   Web of Science ®Google Scholar
• Pedreño M, Sepúlveda M, Armangué T, et al. Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multi Sclerosis Relat Disord. 2019;28:230–234. doi: 10.1016/j.msard.2019.01.007
   PubMed Web of Science ®Google Scholar
• Jarius S, Franciotta D, Bergamaschi R, et al. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med. 2010;48(5):659–663. doi: 10.1515/CCLM.2010.127
   PubMed Web of Science ®Google Scholar
• Velthuis HT, Knop I, Stam P, et al. N latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med. 2011;49(8):1323–1332. doi: 10.1515/CCLM.2011.624
   PubMed Web of Science ®Google Scholar
• Nakano T, Matsui M, Inoue I, et al. Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta. 2011;412(11–12):843–849. doi: 10.1016/j.cca.2011.03.007
   PubMed Web of Science ®Google Scholar
• Hegen H, Milosavljevic D, Schnabl C, et al. Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis. Clin Chem Lab Med. 2018;56(8):1383–1391. doi: 10.1515/cclm-2018-0028
   PubMed Web of Science ®Google Scholar
• Tjernberg I, Johansson M, Henningsson AJ. Diagnostic performance of cerebrospinal fluid free light chains in lyme neuroborreliosis - a pilot study. Clin Chem Lab Med. 2019;57(12):2008–2018. doi: 10.1515/cclm-2019-0315
   PubMed Web of Science ®Google Scholar
• Deschamps R, Shor N, Papeix C, et al. Relevance of kappa free light chains index in patients with aquaporin-4 or myelin-oligodendrocyte-glycoprotein antibodies. Eur J Neurol. 2023;30(9):2865–2869. doi: 10.1111/ene.15897
   PubMedGoogle Scholar
• Hegen H, Walde J, Berek K, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2023;29(2):169–181. doi: 10.1177/13524585221134213
   PubMed Web of Science ®Google Scholar
• Hegen H, Arrambide G, Gnanapavan S, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a consensus statement. Mult Scler. 2023;29(2):182–195. doi: 10.1177/13524585221134217
   PubMed Web of Science ®Google Scholar
• Presslauer S, Milosavljevic D, Huebl W, et al. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study. Mult Scler. 2016;22(4):502–510. doi: 10.1177/1352458515594044
   PubMed Web of Science ®Google Scholar
• Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, et al. Kappa free light chains is a valid tool in the diagnostics of MS: a large multicenter study. Mult Scler. 2020;26(8):912–923. doi: 10.1177/1352458519845844
   PubMed Web of Science ®Google Scholar
• Berek K, Bsteh G, Auer M, et al. Kappa-free light chains in CSF predict early multiple sclerosis disease activity. Neurol(r) Neuroimmunol Neuroinflammation. 2021;8(4):e1005. doi: 10.1212/NXI.0000000000001005
   PubMed Web of Science ®Google Scholar
• Hegen H, Berek K, Bsteh G, et al. Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study. EBioMedicine. 2023;91:104573.
   PubMed Web of Science ®Google Scholar
• Rosenstein I, Axelsson M, Novakova L, et al. Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple sclerosis. J Neurol. 2023;270(10):4800–4811. doi: 10.1007/s00415-023-11817-9
   PubMed Web of Science ®Google Scholar
• Süße M, Feistner F, Grothe M, et al. Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy. Neurol(r) Neuroimmunol Neuroinflammation. 2020;7(6):e892. doi: 10.1212/NXI.0000000000000892
   PubMed Web of Science ®Google Scholar
• Holm Hansen R, Talbot J, Højsgaard Chow H, et al. Increased Intrathecal Activity of Follicular Helper T Cells in patients with relapsing-remitting multiple sclerosis. Neurol(r) Neuroimmunol Neuroinflammation. 2022;9(5):e200009. doi: 10.1212/NXI.0000000000200009
   PubMed Web of Science ®Google Scholar
• Rao DA. T cells that help B cells in chronically inflamed tissues. Front Immunol. 2018;9:1924. doi: 10.3389/fimmu.2018.01924
   PubMed Web of Science ®Google Scholar
• Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19(7):696–707. doi: 10.1038/s41590-018-0135-x
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–220. doi: 10.1056/NEJMoa1606468
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221–234. doi: 10.1056/NEJMoa1601277
   PubMed Web of Science ®Google Scholar
• Pachner A. The brave new world of early treatment of multiple sclerosis: using the molecular biomarkers CXCL13 and neurofilament light to optimize immunotherapy. Biomedicines. 2022;10(9):2099. doi: 10.3390/biomedicines10092099
   PubMed Web of Science ®Google Scholar
• Bai Z, Chen D, Wang L, et al. Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: a systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients. Front Neurosci. 2019;13:1026. doi: 10.3389/fnins.2019.01026
   PubMed Web of Science ®Google Scholar
• Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler. 2011;17(3):335–343. doi: 10.1177/1352458510389102
   PubMed Web of Science ®Google Scholar
• Pike SC, Gilli F, Pachner AR. The CXCL13 Index as a predictive biomarker for activity in clinically isolated syndrome. Int J Mol Sci. 2023;24(13):11050. doi: 10.3390/ijms241311050
   PubMed Web of Science ®Google Scholar
• DiSano KD, Gilli F, Pachner AR. Intrathecally produced CXCL13: a predictive biomarker in multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;6(4):2055217320981396. doi: 10.1177/2055217320981396
   Google Scholar
• Erhart DK, Klose V, Schäper T, et al. CXCL13 in cerebrospinal fluid: clinical value in a Large Cross-Sectional Study. Int J Mol Sci. 2023;25(1):425. doi: 10.3390/ijms25010425
   PubMed Web of Science ®Google Scholar
• Hofer LS, Mariotto S, Wurth S, et al. Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. Mult Scler J Exp Transl Clin. 2019;5(2):2055217319848463. doi: 10.1177/2055217319848463
   Google Scholar
• Bauer A, Rudzki D, Berek K, et al. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Front Immunol. 2022;13:1037812. doi: 10.3389/fimmu.2022.1037812
   PubMed Web of Science ®Google Scholar
• Masouris I, Klein M, Ködel U. The potential for CXCL13 in CSF as a differential diagnostic tool in central nervous system infection. Expert Rev Anti Infect Ther. 2020;18(9):875–885. doi: 10.1080/14787210.2020.1770596
   PubMed Web of Science ®Google Scholar
• Bonneh-Barkay D, Bissel SJ, Kofler J, et al. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22(4):530–546. doi: 10.1111/j.1750-3639.2011.00550.x
   PubMed Web of Science ®Google Scholar
• Lee CG, Da Silva CA, Dela Cruz CS, et al. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73(1):479–501. doi: 10.1146/annurev-physiol-012110-142250
   PubMed Web of Science ®Google Scholar
• Burman J, Raininko R, Blennow K, et al. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol. 2016;292:52–57. doi: 10.1016/j.jneuroim.2016.01.013
   PubMed Web of Science ®Google Scholar
• Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler. 2015;21(14):1761–1770. doi: 10.1177/1352458515574148
   PubMed Web of Science ®Google Scholar
• Baldacci F, Lista S, Palermo G, et al. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics. 2019;16(7):593–600. doi: 10.1080/14789450.2019.1628643
   PubMed Web of Science ®Google Scholar
• Cubas-Núñez L, Gil-Perotín S, Castillo-Villalba J, et al. Potential role of CHI3L1+ astrocytes in progression in MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e972. doi: 10.1212/NXI.0000000000000972
   PubMed Web of Science ®Google Scholar
• Qi Y, Chou L-S, Zhang L-J, et al. Increased cerebrospinal fluid YKL-40 levels are associated with disease severity of neuromyelitis optica spectrum disorders. Multi Sclerosis Relat Disord. 2020;45:102395. doi: 10.1016/j.msard.2020.102395
   PubMed Web of Science ®Google Scholar
• Li J, He Y, Wang H, et al. Microglial/Macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders. Brain Behav. 2022;12(12):e2798. doi: 10.1002/brb3.2798
   PubMed Web of Science ®Google Scholar
• Wang Y-L, Zhu M-Y, Yuan Z-F, et al. Proteomic profiling of cerebrospinal fluid in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease. World J Pediatr. 2022;20(3):259–271. doi: 10.1007/s12519-022-00661-y
   PubMed Web of Science ®Google Scholar
• Kušnierová P, Zeman D, Hradílek P, et al. Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases. PLoS One. 2020;15(5):e0233519. doi: 10.1371/journal.pone.0233519
   PubMed Web of Science ®Google Scholar
• Comabella M, Fernández M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain. 2010;133(Pt 4):1082–1093. doi: 10.1093/brain/awq035
   PubMed Web of Science ®Google Scholar
• de FC, Lucchini M, Lucchetti D, et al. The predictive value of CSF multiple assay in multiple sclerosis: a single center experience. Multi Sclerosis Relat Disord. 2019;35:176–181. doi: 10.1016/j.msard.2019.07.030
   PubMed Web of Science ®Google Scholar
• Cantó E, Tintoré M, Villar LM, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138(Pt 4):918–931. doi: 10.1093/brain/awv017
   PubMed Web of Science ®Google Scholar
• Hinsinger G, Galéotti N, Nabholz N, et al. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler. 2015;21(10):1251–1261. doi: 10.1177/1352458514561906
   PubMed Web of Science ®Google Scholar
• Tarlinton RE, Martynova E, Rizvanov AA, et al. Role of viruses in the pathogenesis of multiple sclerosis. Viruses. 2020;12(6):643. doi: 10.3390/v12060643
   PubMed Web of Science ®Google Scholar
• Sharma K, Chaudhary D, Beard K, et al. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients. Multi Sclerosis Relat Disord. 2022;59:103675. doi: 10.1016/j.msard.2022.103675
   PubMed Web of Science ®Google Scholar
• Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301. doi: 10.1126/science.abj8222
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75–82. doi: 10.1038/35095584
   PubMed Web of Science ®Google Scholar
• Kuchroo VK, Weiner HL. How does Epstein-Barr virus trigger MS? Immunity. 2022;55(3):390–392. doi: 10.1016/j.immuni.2022.02.008
   PubMed Web of Science ®Google Scholar
• Bjornevik K, Münz C, Cohen JI, et al. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19(3):160–171. doi: 10.1038/s41582-023-00775-5
   PubMed Web of Science ®Google Scholar
• Soldan SS, Lieberman PM. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21(1):51–64. doi: 10.1038/s41579-022-00770-5
   PubMed Web of Science ®Google Scholar
• Rojas M, Restrepo-Jiménez P, Monsalve DM, et al. Molecular mimicry and autoimmunity. J Autoimmun. 2018;95:100–123. doi: 10.1016/j.jaut.2018.10.012
   PubMed Web of Science ®Google Scholar
• Vietzen H, Berger SM, Kühner LM, et al. Ineffective control of epstein-barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell. 2023;186(26):5705–5718.e13. doi: 10.1016/j.cell.2023.11.015
   PubMed Web of Science ®Google Scholar
• Lanz TV, Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321–327. doi: 10.1038/s41586-022-04432-7
   PubMed Web of Science ®Google Scholar
• Lünemann JD, Jelcić I, Roberts S, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008;205(8):1763–1773. doi: 10.1084/jem.20072397
   PubMed Web of Science ®Google Scholar
• Tengvall K, Huang J, Hellström C, et al. Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc Natl Acad Sci U S A. 2019;116(34):16955–16960. doi: 10.1073/pnas.1902623116
   PubMed Web of Science ®Google Scholar
• van Noort JM, Bajramovic JJ, Plomp AC, et al. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol. 2000;105(1):46–57. doi: 10.1016/S0165-5728(00)00181-8
   PubMed Web of Science ®Google Scholar
• Hedström AK. Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection. Front Immunol. 2023;14:1212676. doi: 10.3389/fimmu.2023.1212676
   PubMed Web of Science ®Google Scholar
• Hayward A, Grabherr M, Jern P. Broad-scale phylogenomics provides insights into retrovirus-host evolution. Proc Natl Acad Sci U S A. 2013;110(50):20146–20151. doi: 10.1073/pnas.1315419110
   PubMed Web of Science ®Google Scholar
• Nali LH, Olival GS, Montenegro H, et al. Human endogenous retrovirus and multiple sclerosis: a review and transcriptome findings. Multi Sclerosis Relat Disord. 2022;57:103383. doi: 10.1016/j.msard.2021.103383
   PubMed Web of Science ®Google Scholar
• Sedighi S, Gholizadeh O, Yasamineh S, et al. Comprehensive investigations relationship between viral infections and multiple sclerosis pathogenesis. Curr Microbiol. 2022;80(1):15. doi: 10.1007/s00284-022-03112-z
   PubMed Web of Science ®Google Scholar
• Morris G, Maes M, Murdjeva M, et al. Do human endogenous retroviruses contribute to multiple sclerosis, and if so, how? Mol Neurobiol. 2019;56(4):2590–2605. doi: 10.1007/s12035-018-1255-x
   PubMed Web of Science ®Google Scholar
• Latifi T, Zebardast A, Marashi SM. The role of human endogenous retroviruses (HERVs) in Multiple Sclerosis and the plausible interplay between HERVs, Epstein-Barr virus infection, and vitamin D. Multi Sclerosis Relat Disord. 2022;57:103318. doi: 10.1016/j.msard.2021.103318
   PubMed Web of Science ®Google Scholar
• Gholami Barzoki M, Shatizadeh Malekshahi S, Heydarifard Z, et al. The important biological roles of syncytin-1 of human endogenous retrovirus W (HERV-W) and syncytin-2 of HERV-FRD in the human placenta development. Mol Biol Rep. 2023;50(9):7901–7907. doi: 10.1007/s11033-023-08658-0
   PubMed Web of Science ®Google Scholar
• Wieland L, Schwarz T, Engel K, et al. Epstein-barr virus-induced genes and endogenous retroviruses in immortalized B cells from patients with multiple sclerosis. Cells. 2022;11(22):3619. doi: 10.3390/cells11223619
   PubMed Web of Science ®Google Scholar
• Sutkowski N, Conrad B, Thorley-Lawson DA, et al. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity. 2001;15(4):579–589. doi: 10.1016/S1074-7613(01)00210-2
   PubMed Web of Science ®Google Scholar
• Bergallo M, Pinon M, Galliano I, et al. Epstein Barr virus induces HERV-K and HERV-W expression in pediatrics liver transplant recipients? Minerva Pediatr. 2020;72(3):145–148. doi: 10.23736/S0026-4946.16.04472-8
   PubMed Web of Science ®Google Scholar
• Meier U-C, Cipian RC, Karimi A, et al. Cumulative roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human herpes Virus-6 in driving an inflammatory cascade underlying MS pathogenesis. Front Immunol. 2021;12:757302. doi: 10.3389/fimmu.2021.757302
   PubMed Web of Science ®Google Scholar
• Luca VD, Martins Higa A, Malta Romano C, et al. Cross-reactivity between myelin oligodendrocyte glycoprotein and human endogenous retrovirus W protein: nanotechnological evidence for the potential trigger of multiple sclerosis. Micron. 2019;120:66–73. doi: 10.1016/j.micron.2019.02.005
   PubMed Web of Science ®Google Scholar
• Engdahl E, Gustafsson R, Huang J, et al. Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis. Front Immunol. 2019;10:2715. doi: 10.3389/fimmu.2019.02715
   PubMed Web of Science ®Google Scholar
• Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005;352(8):768–776. doi: 10.1056/NEJMoa042207
   PubMed Web of Science ®Google Scholar
• Lucas RM, Lay M-L, Grant J, et al. Risk of a first clinical diagnosis of central nervous system demyelination in relation to human herpesviruses in the context of Epstein-Barr virus. Eur J Neurol. 2023;30(9):2752–2760. doi: 10.1111/ene.15919
   PubMedGoogle Scholar
• Lundström W, Gustafsson R. Human herpesvirus 6A is a risk factor for multiple sclerosis. Front Immunol. 2022;13:840753. doi: 10.3389/fimmu.2022.840753
   PubMedGoogle Scholar
• Xu L, Zhang L-J, Yang L, et al. Positive association of herpes simplex virus-IgG with multiple sclerosis: a systematic review and meta-analysis. Multi Sclerosis Relat Disord. 2021;47:102633. doi: 10.1016/j.msard.2020.102633
   PubMed Web of Science ®Google Scholar
• Khalesi Z, Tamrchi V, Razizadeh MH, et al. Association between human herpesviruses and multiple sclerosis: a systematic review and meta-analysis. Microb Pathog. 2023;177:106031. doi: 10.1016/j.micpath.2023.106031
   PubMed Web of Science ®Google Scholar
• Pi K-S, Bortolotti D, Sang Y, et al. Studying the interactions of U24 from HHV-6 in order to further elucidate its potential role in MS. Viruses. 2022;14(11):2384. doi: 10.3390/v14112384
   PubMed Web of Science ®Google Scholar
• Tao C, Simpson-Yap S, Taylor B, et al. Markers of Epstein-Barr virus and human herpesvirus-6 infection and multiple sclerosis clinical progression. Multi Sclerosis Relat Disord. 2022;59:103561. doi: 10.1016/j.msard.2022.103561
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PloS One. 2009;4(11):e7638. doi: 10.1371/journal.pone.0007638
   PubMed Web of Science ®Google Scholar
• Felgenhauer K, Reiber H. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system. Clin Investig. 1992;70(1):28–37. doi: 10.1007/BF00422934
   PubMedGoogle Scholar
• Persson L, Longhi S, Enarsson J, et al. Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production. J Clin Virol. 2014;61(1):107–112. doi: 10.1016/j.jcv.2014.06.011
   PubMed Web of Science ®Google Scholar
• Rosche B, Laurent S, Conradi S, et al. Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis. PloS One. 2012;7(1):e28094. doi: 10.1371/journal.pone.0028094
   PubMed Web of Science ®Google Scholar
• Kofahi RM, Kofahi HM, Sabaheen S, et al. Prevalence of seropositivity of selected herpesviruses in patients with multiple sclerosis in the north of Jordan. BMC neurol. 2020;20(1):397. doi: 10.1186/s12883-020-01977-w
   PubMed Web of Science ®Google Scholar
• Jarius S, Eichhorn P, Jacobi C, et al. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci. 2009;280(1–2):98–100. doi: 10.1016/j.jns.2008.08.002
   PubMed Web of Science ®Google Scholar
• Jarius S, Franciotta D, Bergamaschi R, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2008;79(10):1134–1136. doi: 10.1136/jnnp.2007.133330
   PubMed Web of Science ®Google Scholar
• Levine KS, Leonard HL, Blauwendraat C, et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron. 2023;111(7):1086–1093.e2. doi: 10.1016/j.neuron.2022.12.029
   PubMed Web of Science ®Google Scholar
• Perlejewski K, Bukowska-Ośko I, Nakamura S, et al. Metagenomic Analysis of Cerebrospinal Fluid from patients with multiple sclerosis. Adv Exp Med Biol. 2016;935:89–98.
   PubMed Web of Science ®Google Scholar
• Chavarria V, Espinosa-Ramírez G, Sotelo J, et al. Conversion predictors of clinically isolated syndrome to multiple sclerosis in Mexican patients: a prospective study. Arch Med Res. 2023;54(5):102843. doi: 10.1016/j.arcmed.2023.102843
   PubMed Web of Science ®Google Scholar
• Ortega-Hernandez O-D, Martínez-Cáceres EM, Presas-Rodríguez S, et al. Epstein-barr virus and multiple sclerosis: a convoluted interaction and the opportunity to unravel predictive biomarkers. Int J Mol Sci. 2023;24(8):7407. doi: 10.3390/ijms24087407
   PubMed Web of Science ®Google Scholar
• Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–870. doi: 10.1002/ana.24954
   PubMed Web of Science ®Google Scholar
• Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Laboratory Med (Cclm). 2016;54(10):1655–1661. doi: 10.1515/cclm-2015-1195
   Google Scholar
• Dalla Costa G, Martinelli V, Sangalli F, et al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology. 2019;92(7):e733–e741. doi: 10.1212/WNL.0000000000006902
   PubMed Web of Science ®Google Scholar
• Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246–257. doi: 10.1016/S1474-4422(22)00009-6
   PubMed Web of Science ®Google Scholar
• Siller N, Kuhle J, Muthuraman M, et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult Scler. 2019;25(5):678–686. doi: 10.1177/1352458518765666
   PubMed Web of Science ®Google Scholar
• Varhaug KN, Torkildsen Ø, Myhr K-M, et al. Neurofilament light chain as a biomarker in multiple sclerosis. Front Neurol. 2019;10:338. doi: 10.3389/fneur.2019.00338
   PubMedGoogle Scholar
• Martin S-J, McGlasson S, Hunt D, et al. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies. J Neurol Neurosurg Psychiatry. 2019;90(9):1059–1067. doi: 10.1136/jnnp-2018-319190
   PubMed Web of Science ®Google Scholar
• Bjornevik K, Munger KL, Cortese M, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 2020;77(1):58–64. doi: 10.1001/jamaneurol.2019.3238
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Benkert P, Schaedelin S, et al. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol. 2023;80(12):1317. doi: 10.1001/jamaneurol.2023.3997
   PubMed Web of Science ®Google Scholar
• Åkesson J, Hojjati S, Hellberg S, et al. Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nat Commun. 2023;14(1):6903. doi: 10.1038/s41467-023-42682-9
   PubMed Web of Science ®Google Scholar
• Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76(9):1035–1048. doi: 10.1001/jamaneurol.2019.1534
   PubMed Web of Science ®Google Scholar
• Peng P, Deng H, Li Z, et al. Distinct immune responses in the early phase to natural SARS‐CoV‐2 infection or vaccination. J med virol. 2022;94(12):5691–5701. doi: 10.1002/jmv.28034
   PubMed Web of Science ®Google Scholar
• Kim H, Lee E-J, Kim S, et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol(r) Neuroimmunol Neuroinflammation. 2020;7(3):e708. doi: 10.1212/NXI.0000000000000708
   PubMed Web of Science ®Google Scholar
• Fitzgerald KC, Sotirchos ES, Smith MD, et al. Contributors to serum NfL levels in people without neurologic disease. Ann Neurol. 2022;92(4):688–698. doi: 10.1002/ana.26446
   PubMed Web of Science ®Google Scholar
• Manouchehrinia A, Piehl F, Hillert J, et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol. 2020;7(1):139–143. doi: 10.1002/acn3.50972
   PubMed Web of Science ®Google Scholar
• Michetti F, Massaro A, Murazio M. The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett. 1979;11(2):171–175. doi: 10.1016/0304-3940(79)90122-8
   PubMed Web of Science ®Google Scholar
• Michetti F, Clementi ME, Di Liddo R, et al. The S100B protein: a multifaceted pathogenic factor more than a biomarker. Int J Mol Sci. 2023;24(11):9605. doi: 10.3390/ijms24119605
   PubMed Web of Science ®Google Scholar
• Michetti F, D’Ambrosi N, Toesca A, et al. The S100B story: from biomarker to active factor in neural injury. J Neurochem. 2019;148(2):168–187. doi: 10.1111/jnc.14574
   PubMed Web of Science ®Google Scholar
• Camponeschi C, de CM, Amadio S, et al. S100B protein as a therapeutic target in multiple sclerosis: the S100B inhibitor arundic acid protects from chronic experimental autoimmune encephalomyelitis. Int J Mol Sci. 2021;22(24):13558. doi: 10.3390/ijms222413558
   PubMed Web of Science ®Google Scholar
• Barros C, Barateiro A, Neto A, et al. S100B inhibition protects from chronic experimental autoimmune encephalomyelitis. Brain Commun. 2022;4(3):fcac076. doi: 10.1093/braincomms/fcac076
   PubMedGoogle Scholar
• Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain. 2002;125(7):1462–1473. doi: 10.1093/brain/awf165
   PubMedGoogle Scholar
• Rejdak K, Petzold A, Stelmasiak Z, et al. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler. 2008;14(1):59–66. doi: 10.1177/1352458507082061
   PubMed Web of Science ®Google Scholar
• Schaefer JH, Schaller-Paule MA, Wenger K, et al. Relevance of dedicated multiple sclerosis serum biomarkers in predicting contrast enhancement with gadolinium: results from the REDUCE-GAD trial. Eur J Neurol. 2023;30(8):2393–2400. doi: 10.1111/ene.15865
   PubMed Web of Science ®Google Scholar
• Hein Née Maier K, Köhler A, Diem R, et al. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neurosci Lett. 2008;436(1):72–76. doi: 10.1016/j.neulet.2008.02.064
   PubMed Web of Science ®Google Scholar
• Wei Y, Chang H, Li X, et al. CSF-S100B is a potential Candidate biomarker for neuromyelitis optica spectrum disorders. Biomed Res Int. 2018;1–11. 2018 10.1155/2018/5381239
   Web of Science ®Google Scholar
• Jasiak-Zatońska M, Pietrzak A, Wyciszkiewicz A, et al. Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022;56(3):246–255. doi: 10.5603/PJNNS.a2022.0013
   PubMed Web of Science ®Google Scholar
• Leppert D, Watanabe M, Schaedelin S, et al. Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023;94(9):726–737. doi: 10.1136/jnnp-2022-330796
   PubMed Web of Science ®Google Scholar
• Dinoto A, Sechi E, Flanagan EP, et al. Serum and cerebrospinal fluid biomarkers in Neuromyelitis Optica Spectrum Disorder and myelin oligodendrocyte glycoprotein associated disease. Front Neurol. 2022;13:866824. doi: 10.3389/fneur.2022.866824
   PubMed Web of Science ®Google Scholar
• Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry. 2018;89(9):927–936. doi: 10.1136/jnnp-2018-317969
   PubMed Web of Science ®Google Scholar
• Cohen SR, Brune MJ, Herndon RM, et al. Cerebrospinal fluid myelin basic protein and multiple sclerosis. Adv Exp Med Biol. 1978;100:513–519.
   PubMedGoogle Scholar
• Koshihara H, Oguchi K, Takei Y, et al. Meningeal inflammation and demyelination in a patient clinically diagnosed with acute disseminated encephalomyelitis. J Neurol Sci. 2014;346(1–2):323–327. doi: 10.1016/j.jns.2014.08.037
   PubMed Web of Science ®Google Scholar
• Xu S, Lu J, Shao A, et al. Glial cells: role of the immune response in ischemic stroke. Front Immunol. 2020;11:294. doi: 10.3389/fimmu.2020.00294
   PubMed Web of Science ®Google Scholar
• Agliardi C, Guerini FR, Zanzottera M, et al. Myelin basic protein in Oligodendrocyte-Derived Extracellular Vesicles as a diagnostic and prognostic biomarker in multiple sclerosis: a Pilot study. Int J Mol Sci. 2023;24(1):894. doi: 10.3390/ijms24010894
   PubMed Web of Science ®Google Scholar
• Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res. 2015;1600:17–31. doi: 10.1016/j.brainres.2014.12.027
   PubMed Web of Science ®Google Scholar
• Cullen DK, Simon CM, LaPlaca MC. Strain rate-dependent induction of reactive astrogliosis and cell death in three-dimensional neuronal-astrocytic co-cultures. Brain Res. 2007;1158:103–115. doi: 10.1016/j.brainres.2007.04.070
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Junker A, Brettschneider J, et al. Brain-specific cytoskeletal damage markers in cerebrospinal fluid: is there a Common Pattern between amyotrophic lateral sclerosis and primary progressive multiple sclerosis? Int J Mol Sci. 2015;16(8):17565–17588. doi: 10.3390/ijms160817565
   PubMed Web of Science ®Google Scholar
• Camara-Lemarroy C, Metz L, Kuhle J, et al. Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels. Mult Scler J. 2022;28(13):2081–2089. doi: 10.1177/13524585221109761
   PubMed Web of Science ®Google Scholar
• Kassubek R, Gorges M, Schocke M, et al. GFAP in early multiple sclerosis: a biomarker for inflammation. Neurosci Lett. 2017;657:166–170. doi: 10.1016/j.neulet.2017.07.050
   PubMed Web of Science ®Google Scholar
• Martínez MAM, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler. 2015;21(5):550–561. doi: 10.1177/1352458514549397
   PubMed Web of Science ®Google Scholar
• Sun M, Liu N, Xie Q, et al. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: a systematic review and meta-analysis. Multi Sclerosis Relat Disord. 2021;51:102870. doi: 10.1016/j.msard.2021.102870
   PubMed Web of Science ®Google Scholar
• Högel H, Rissanen E, Barro C, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. 2020;26(2):210–219. doi: 10.1177/1352458518819380
   PubMedGoogle Scholar
• Abdelhak A, Hottenrott T, Morenas-Rodríguez E, et al. Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity Marker? Front Neurol. 2019;10:280. doi: 10.3389/fneur.2019.00280
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Huss A, Kassubek J, et al. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798. doi: 10.1038/s41598-018-33158-8
   PubMedGoogle Scholar
• Aktas O, Smith MA, Rees WA, et al. Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol. 2021;89(5):895–910. doi: 10.1002/ana.26067
   PubMed Web of Science ®Google Scholar
• Schindler P, Aktas O, Ringelstein M, et al. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Rev Clin Immunol. 2023;19(1):71–91. doi: 10.1080/1744666X.2023.2148657
   PubMed Web of Science ®Google Scholar
• Kaneko K, Sato DK, Nakashima I, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry. 2016;87(11):1257–1259. doi: 10.1136/jnnp-2015-312676
   PubMed Web of Science ®Google Scholar
• Meier S, Willemse EAJ, Schaedelin S, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 2023;80(3):287–297. doi: 10.1001/jamaneurol.2022.5250
   PubMed Web of Science ®Google Scholar
• Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol. 2023;22(3):268–282. doi: 10.1016/S1474-4422(22)00431-8
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. doi: 10.1212/WNL.0000000000001729
   PubMed Web of Science ®Google Scholar
• Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15(2):89–102.
   PubMed Web of Science ®Google Scholar
• Jarius S, Aktas O, Ayzenberg I, et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis. J Neurol. 2023;270(7):3341–3368.
   PubMed Web of Science ®Google Scholar
• Seil FJ. Myelin Antigens and Antimyelin Antibodies. Antibodies (Basel). 2018;7(1):2. doi: 10.3390/antib7010002
   PubMedGoogle Scholar
• Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflammation. 2020;7(2):e674. doi: 10.1212/NXI.0000000000000674
   PubMed Web of Science ®Google Scholar
• Corbali O, Chitnis T. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Front Neurol. 2023;14:1137998. doi: 10.3389/fneur.2023.1137998
   PubMed Web of Science ®Google Scholar
• Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20(9):762–772. doi: 10.1016/S1474-4422(21)00218-0
   PubMed Web of Science ®Google Scholar
• Lerch M, Bauer A, Reindl M. The potential pathogenicity of Myelin Oligodendrocyte Glycoprotein Antibodies in the optic pathway. J Neuroophthalmol. 2023;43(1):5–16. doi: 10.1097/WNO.0000000000001772
   PubMed Web of Science ®Google Scholar
• Höftberger R, Lassmann H, Berger T, et al. Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept. Nat Rev Neurol. 2022;18(11):681–688.
   PubMed Web of Science ®Google Scholar
• Wang H, Munger KL, Reindl M, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology. 2008;71(15):1142–1146. doi: 10.1212/01.wnl.0000316195.52001.e1
   PubMed Web of Science ®Google Scholar
• Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med. 2007;356(4):371–378. doi: 10.1056/NEJMoa063602
   PubMed Web of Science ®Google Scholar
• Pelayo R, Tintoré M, Montalban X, et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med. 2007;356(4):426–428. doi: 10.1056/NEJMc062467
   PubMed Web of Science ®Google Scholar
• Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003;349(2):139–145. doi: 10.1056/NEJMoa022328
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112. doi: 10.1016/S0140-6736(04)17551-X
   PubMed Web of Science ®Google Scholar
• Weinshenker BG. Neuromyelitis optica is distinct from multiple sclerosis. Arch Neurol. 2007;64(6):899–901. doi: 10.1001/archneur.64.6.899
   PubMedGoogle Scholar
• Prüss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21(12):798–813.
   PubMed Web of Science ®Google Scholar
• Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85. doi: 10.1038/s41572-020-0214-9
   PubMed Web of Science ®Google Scholar
• Poopalasundaram S, Knott C, Shamotienko OG, et al. Glial heterogeneity in expression of the inwardly rectifying K+ channel, Kir4.1, in adult rat CNS. Glia. 2000;30(4):362–372. doi: 10.1002/(SICI)1098-1136(200006)30:4<362:AID-GLIA50>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Kalsi AS, Greenwood K, Wilkin G, et al. Kir4.1 expression by astrocytes and oligodendrocytes in CNS white matter: a developmental study in the rat optic nerve. J Anat. 2004;204(6):475–485. doi: 10.1111/j.0021-8782.2004.00288.x
   PubMed Web of Science ®Google Scholar
• Tang X, Taniguchi K, Kofuji P. Heterogeneity of Kir4.1 channel expression in glia revealed by mouse transgenesis. Glia. 2009;57(16):1706–1715. doi: 10.1002/glia.20882
   PubMed Web of Science ®Google Scholar
• Larson VA, Mironova Y, Vanderpool KG, et al. Oligodendrocytes control potassium accumulation in white matter and seizure susceptibility. Elife. 2018;7:e34829. doi: 10.7554/eLife.34829
   PubMed Web of Science ®Google Scholar
• Masaki H, Wakayama Y, Hara H, et al. Immunocytochemical studies of aquaporin 4, Kir4.1, and α1-syntrophin in the astrocyte endfeet of mouse brain capillaries. Acta Histochem Cytochem. 2010;43(4):99–105. doi: 10.1267/ahc.10016
   PubMed Web of Science ®Google Scholar
• Butt AM, Kalsi A. Inwardly rectifying potassium channels (kir) in central nervous system glia: a special role for Kir4.1 in glial functions. J Cell Mol Med. 2006;10(1):33–44. doi: 10.1111/j.1582-4934.2006.tb00289.x
   PubMed Web of Science ®Google Scholar
• Nwaobi SE, Cuddapah VA, Patterson KC, et al. The role of glial-specific Kir4.1 in normal and pathological states of the CNS. Acta Neuropathol. 2016;132(1):1–21. doi: 10.1007/s00401-016-1553-1
   PubMed Web of Science ®Google Scholar
• Hibino H, Inanobe A, Furutani K, et al. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev. 2010;90(1):291–366. doi: 10.1152/physrev.00021.2009
   PubMed Web of Science ®Google Scholar
• Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2012;367(2):115–123. doi: 10.1056/NEJMoa1110740
   PubMed Web of Science ®Google Scholar
• Nicot AB, Harb J, Garcia A, et al. Aglycosylated extracellular loop of inwardly rectifying potassium channel 4.1 (KCNJ10) provides a target for autoimmune neuroinflammation. Brain Commun. 2023;5(2):fcad044. doi: 10.1093/braincomms/fcad044
   PubMedGoogle Scholar
• Chastre A, Hafler DA, O’Connor KC. Evaluation of KIR4.1 as an immune target in multiple sclerosis. N Engl J Med. 2016;374(15):1495–1496. doi: 10.1056/NEJMc1513302
   PubMed Web of Science ®Google Scholar
• Brill L, Goldberg L, Karni A, et al. Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse? Mult Scler. 2015;21(5):572–579. doi: 10.1177/1352458514551779
   PubMed Web of Science ®Google Scholar
• Hemmer B. Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies–conflicting results? Mult Scler. 2015;21(5):537–539. doi: 10.1177/1352458514564493
   PubMed Web of Science ®Google Scholar
• Kraus V, Srivastava R, Kalluri SR, et al. Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease. Neurology. 2014;82(6):470–473. doi: 10.1212/WNL.0000000000000097
   PubMed Web of Science ®Google Scholar
• Higuchi O, Nakane S, Sakai W, et al. Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO. Neurol(r) Neuroimmunol Neuroinflammation. 2016;3(5):e263. doi: 10.1212/NXI.0000000000000263
   PubMed Web of Science ®Google Scholar
• Yaldizli Ö, Janiaud P, Benkert P, et al. Personalized treatment decision algorithms for the clinical implementation of serum neurofilament light chain in multiple sclerosis: a modified Delphi study [poster presented at the 9th joint ECTRIMS-ACTRIMS meeting Milan]. 2023 Oct 11–13. Available from: https://apps.congrex.com/ectrims2023/en-GB/pag/presentation/355278.
   Google Scholar
• Altmann P, Leutmezer F, Zach H, et al. Serum neurofilament light chain withstands delayed freezing and repeated thawing. Sci Rep. 2020;10(1):19982. doi: 10.1038/s41598-020-77098-8
   PubMed Web of Science ®Google Scholar
• Keshavan A, Heslegrave A, Zetterberg H, et al. Stability of blood-based biomarkers of Alzheimer’s disease over multiple freeze-thaw cycles. Alzheimers Dement (Amst). 2018;10:448–451. doi: 10.1016/j.dadm.2018.06.001
   PubMedGoogle Scholar
• Hörber S, Klein R, Peter A. Effects of long-term storage on serum free light chain stability. Clin Lab. 2019;65(5). doi: 10.7754/Clin.Lab.2018.181107
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Thanei G-A, Harp C, et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023;93:104662. doi: 10.1016/j.ebiom.2023.104662
   PubMed Web of Science ®Google Scholar
• Bittner S, Steffen F, Uphaus T, et al. Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine. 2020;56:102807. doi: 10.1016/j.ebiom.2020.102807
   PubMed Web of Science ®Google Scholar
• Cantó E, Barro C, Zhao C, et al. Association Between Serum Neurofilament Light Chain Levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. 2019;76(11):1359–1366. doi: 10.1001/jamaneurol.2019.2137
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343(13):938–952. doi: 10.1056/NEJM200009283431307
   PubMed Web of Science ®Google Scholar